# TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)

> **NCT02480751** · PHASE2 · COMPLETED · sponsor: **Toray Industries, Inc** · enrollment: 113 (actual)

## Conditions studied

- Renal Insufficiency, Chronic

## Interventions

- **DRUG:** Beraprost
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02480751
- **Lead sponsor:** Toray Industries, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2008-05
- **Final completion:** —
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2015-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02480751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02480751, "TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT02480751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*